Abstract:Schistosomiasis is a major neglected parasitic disease that affects more than 240 million people worldwide caused by Platyhelminthes of the genus Schistosoma . The treatment of schistosomiasis relies on the long-term application of a single safe drug, praziquantel (PZQ). Unfortunately, PZQ is very effective on adult parasites and poorly on larval stage and immature juvenile worms; this can partially explain the re-infection in endemic areas where patients are likely to host parasites at different developmental stages concurrently. Moreover, the risk of development of drug resistance because of the widespread use of a single drug in a large population is nowadays a serious threat. Hence, research aimed at identifying novel drugs to be used alone or in combination with PZQ is needed. Schistosomes display morphologically distinct stages during their life cycle and epigenetic mechanisms are known to play important roles in parasite growth, survival, and development. Histone deacetylase (HDAC) enzymes, particularly HDAC8, are considered valuable for therapeutic intervention for the treatment of schistosomiasis. Herein, we report the phenotypic screening on both larvae and adult Schistosoma mansoni stages of structurally different HDAC inhibitors selected from the in-house Siena library. All molecules have previously shown inhibition profiles on human HDAC6 and/or HDAC8 enzymes. Among them we identified a quinolone-based HDAC inhibitor, NF2839, that impacts larval and adult parasites as well as egg viability and maturation in vitro . Importantly, this quinolone-based compound also increases histone and tubulin acetylation in S . mansoni parasites, thus representing a leading candidate for the development of new generation anti-Schistosoma chemotherapeutics. Neglected tropical diseases, such as schistosomiasis, which is caused by parasitic worms, represent serious public health problems in many countries around the world. Schistosoma mansoni is the major parasitic platyhelminth species causing intestinal schistosomiasis. Currently the control of schistosomiasis is heavily reliant on the drug praziquantel (PZQ) that it is unfortunately not highly effective against larval and immature worm stages. The use of PZQ in mass treatment programs means that the development of resistance is likely, therefore identifying novel drug targets and their associated compounds is critical. Drugs that inhibit enzymes that modify the chromatin structure have been developed for several diseases. We and others have shown that S . mansoni epigenetic enzymes are also potential therapeutic targets. Here, we evaluate and characterize several histone deacetylases (HDAC) inhibitors on the larval and adult stage of Schistosoma mansoni and report the anti-parasitic profile of these compounds. Some of the HDAC inhibitors tested showed potent effects, particularly NF2839, that impacts larval and adult parasites as well as egg viability and maturation. The findings of this study provide a starting point for the development of new HDAC-based schistosomicidal compounds.

Schistosomicidal evaluation of flavonoids from two species of Styrax against Schistosoma mansoni adult worms

In vivo antischistosomal efficacy of Porcelia ponderosa γ-lactones

Efficacy of spilanthol and Acmella oleracea (L.) R. K. Jansen (Asteraceae) extract against Schistosoma mansoni infection

Targeting the Schistosoma mansoni nutritional mechanisms to design new antischistosomal compounds

Sanguinarine: an alkaloid with promising in vitro and in vivo antiparasitic activity against different developmental stages of Schistosoma mansoni and in silico pharmacokinetic properties (ADMET)

In vitro and In silico assessment of antischistosomal activities of ethanolic extract of Cornulacamonacantha

Traditional Kenyan herbal medicine: exploring natural products' therapeutics against schistosomiasis

Evaluation of Lignans from Piper cubeba against Schistosoma mansoni Adult Worms: A Combined Experimental and Theoretical Study

EDBD—3,6-Epidioxy-1,10-Bisaboladiene—An Endoperoxide Sesquiterpene Obtained from Drimys brasiliensis (Winteraceae) Exhibited Potent Preclinical Efficacy against Schistosoma mansoni Infection

Effects of Abelmoschus esculentus Extracts and Fractions on Embryos and Adult Individuals of Biomphalaria glabrata (Say, 1818) and on Schistosoma mansoni Cercariae

In Vitro Schistosomicidal Activity of the Alkaloid-Rich Fraction from Ruta graveolens L. (Rutaceae) and Its Characterization by UPLC-QTOF-MS

In Silico Comparison of Bioactive Compounds Characterized from Azadirachta indica with an FDA-Approved Drug against Schistosomal Agents: New Insight into Schistosomiasis Treatment

In vitro antischistosomal activity of 2-aroyl-benzofuran derivatives against Schistosoma mansoni

Integration and use of Schistosoma mansoni genomic data towards the identification of candidate therapeutic targets

Antischistosomal Properties of Hederacolchiside A1 Isolated from Pulsatilla chinensis

In Situ Preparation of Dehydrodieugenol‐Loaded Silver Nanoparticles and their Antischistosomal Activity

Evaluation of Antischistosomal Activities of Crude Aqueous Extracts of Artemisia annua, Nigella sativa, and Allium sativum against Schistosoma mansoni in Hamsters

Anti-Inflammatory Properties of Menthol and Menthone in Schistosoma mansoni Infection

Multitarget anti-parasitic activities of isoquinoline alkaloids isolated from Hippeastrum aulicum (Amaryllidaceae)

Chemical Constituents from Aerial Parts of Baccharis sphenophylla and Effects against Intracellular Forms of Trypanosoma cruzi

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S . mansoni larval and adult worm stages